新型冠状病毒肺炎疫情下肾上腺疾病管理专家建议

doi:10.16150/j.1671-2870.2022.02.007

摘要/Abstract

摘要：

新型冠状病毒（新冠）奥密克戎（Omicron）变异株感染疫情在世界各地出现了广泛传播,并且逐渐影响中国。部分新冠感染者合并有各种基础疾病,其中肾上腺疾病可导致全身糖、脂、水盐代谢失衡,影响新冠感染者的预后。肾上腺疾病诊疗的专科性较强,非专科医师对该病的认识可能存在不足,成为肾上腺疾病合并新冠感染患者病情控制的难点。本专家建议旨在规范临床认识,指导临床实践,尤其在复杂的疫情防控下,为新冠流行期间的肾上腺疾病诊断、治疗以及随访的综合管理提供必要的参考依据和指导意见。

关键词: 新型冠状病毒肺炎, 奥密克戎, 肾上腺疾病, 库欣综合征, 醛固酮增多症, 嗜铬细胞瘤/副神经节瘤, 肾上腺皮质癌, 肾上腺皮质功能减退

Abstract:

A new hit of severe acute respiratory syndrome coronavirus 2 variant strain Omicron pandemic is spreading worldwide and gradually affecting China. Adrenal disease severely affects the balance of glucose, lipids, water and salts throughout the body, thus affecting the prognosis of patients with coronavirus disease 2019 (COVID-19). At the same time, it has become a key point on management of COVID-19 with adrenal disease, due to its specialty and lack of clinical understanding. The purpose of this expert suggestion is to standardize the clinical understanding and guide clinical practice. Especially in the context of complex epidemic prevention and control, it provides necessary reference basis and guidance for the diagnosis, treatment and comprehensive management of adrenal diseases during the current COVID-19 epidemic.

Key words: COVID-19, Omicron, Adrenal disease, Cushing′s syndrome, Aldosteronism, Pheochromocytoma/paraganglioma, Adrenocortical carcinoma, Adrenocortical hypofunction

中图分类号:

R586

中华医学会内分泌学分会. 新型冠状病毒肺炎疫情下肾上腺疾病管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 139-142.

Chinese Society of Endocrinology,Chinese Medical Association , et al . Expert suggestion for adrenal diseases management during the recent COVID-19 pandemic[J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 139-142.

参考文献 19

[1]	中国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版)[J]. 国际流行病学传染病学杂志, 2022, 49(2):73-80.
	China National Health Commission. Diagnosis and treatment plan for novel coronavirus pneumonia (trial version 9)[J]. Int J Epidemiol Infect Dis, 2022, 49(2):73-80.
[2]	Zhang X, Zhang W, Chen S. Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic[J]. Lancet, 2022, 399(10340):2011-2012. doi: 10.1016/S0140-6736(22)00838-8 URL
[3]	Seiglie J, Platt J, Cromer SJ, et al. Diabetes as a Risk Factor for Poor Early Outcomes in Patients Hospitalized With COVID-19[J]. Diabetes Care, 2020, 43(12):2938-2944. doi: 10.2337/dc20-1506 URL
[4]	Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study[J]. Lancet Diabetes Endocrinol, 2020, 8(10):813-822. doi: 10.1016/S2213-8587(20)30272-2 URL
[5]	African COVID-19 Critical Care Outcomes Study ACCCOS Investigators. Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study[J]. Lancet, 2021, 397(10288):1885-1894. doi: 10.1016/S0140-6736(21)00441-4 URL
[6]	Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study[J]. Lancet, 2022, 399(10335):1618-1624. doi: 10.1016/S0140-6736(22)00327-0 URL
[7]	Yonekawa A, Shimono N. Clinical Significance of COVID-19 and Diabetes: In the Pandemic Situation of SARS-CoV-2 Variants including Omicron(B.1.1.529)[J]. Biology(Basel), 2022, 11(3):400.
[8]	Arlt W, Baldeweg SE, Pearce SHS, et al. ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency[J]. Eur J Endocrinol, 2020, 183(1):G25-G32. doi: 10.1530/EJE-20-0361 URL
[9]	中华医学会内分泌学分会. 库欣综合征专家共识(2011年)[J]. 中华内分泌代谢杂志, 2012, 28(2):96-102.
	Endocrinology branch of Chinese Medical Association. Expert consensus on Cushing syndrome (2011)[J]. Chin J Endocrinol Metab, 2012, 28(2):96-102.
[10]	Lisco G, De Tullio A, Stragapede A, et al. COVID-19 and the Endocrine System: A Comprehensive Review on the Theme[J]. J Clin Med, 2021, 10(13):2920. doi: 10.3390/jcm10132920 URL
[11]	中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9):727-736.
	Endocrinology branch of Chinese Medical Association. Expert consensus on diagnosis and treatment of primary aldosteronism(2020 Edition)[J]. Chin J Endocrinol Metab, 2020, 36(9):727-736.
[12]	中华医学会内分泌学分会. 嗜铬细胞瘤和副神经节瘤诊断治疗专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9):737-750.
	Endocrinology branch of Chinese Medical Association. Expert consensus on diagnosis and treatment of pheochromocytoma and paraganglioma (2020 Edition)[J]. Chin J Endocrinol Metab, 2020, 36(9):737-750.
[13]	Trisha M, Sinha AG. Asymptomatic Pheochromocytoma With Delayed Resection Due to Covid-19 and Persistent Postoperative Hypertension[J]. J Endoc Soc, 2021(Supple 1):Supplement_1.
[14]	Kong N, Singh N, Mazzone S, et al. Takotsubo Syndrome Presenting as Cardiogenic Shock in Patients With COVID-19: A Case Series and Review of Current Literature[J]. Cardiovasc Revasc Med, 2021, 28S:50-53.
[15]	Clark DE, Dendy JM, Li DL, et al. Cardiovascular magnetic resonance evaluation of soldiers after recovery from symptomatic SARS-CoV-2 infection: a case-control study of cardiovascular post-acute sequelae of SARS-CoV-2 infection (CV PASC)[J]. J Cardiovascul Magn Resonan, 2021, 23(1):1-9. doi: 10.1186/s12968-020-00692-2 URL
[16]	中华医学会内分泌学分会肥胖学组. 肾上腺皮质功能减退症患者围手术期糖皮质激素管理专家共识[J]. 中华内分泌代谢杂志, 2022, 38(1):1-6.
	Obesity group, endocrinology branch, Chinese Medical Association. Expert consensus on perioperative glucocorticoid management in patients with adrenocortical insufficiency[J]. Chin J Endocrinol Metab, 2022, 38(1):1-6.
[17]	Arlt W, Baldeweg SE, Pearce SHS, et al. ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency[J]. Eur J Endocrinol, 2020, 183(1):G25-G32. doi: 10.1530/EJE-20-0361 URL
[18]	Raghavan D, Tan AR, Story ES, et al. Management changes for patients with endocrine-related cancers in the COVID-19 pandemic[J]. Endocr Relat Cancer, 2020, 27(9):R357-R374. doi: 10.1530/ERC-20-0229 URL
[19]	Zhang Y, Wang W, Ning G. Metabolic Management Center: An innovation project for the management of metabolic diseases and complications in China[J]. J Diabetes, 2019, 11(1):11-13. doi: 10.1111/1753-0407.12847 URL